Safety Profile of RINVOQ™ (upadacitinib): Analysis of Up to ~3.5 Years of Exposure in Patients With Rheumatoid Arthritis
Sponsored by AbbVie Medical Affairs
Jul 01, 2020
RA/Inflammatory arthritis
In this week's podcast, Drs. Artie Kavanaugh and Jack Cush present highlights from the virtual EULAR2020 meeting held June 3-6, 2020. Featured reports include:
SELECT-CHOICE study. ABA vs. UPA in…
Muscles and Tendons in RA
Dr. David Liew from EULAR2020 Virtual Conference RA beyond the joints
- Tenosynovitis as a predictor, MRI and muscle changes in RA
Autoinflammatory/Still's Disease Panel - EULAR2020
Drs. Olga Petryna, Petros Efthimiou, Apostolos Kontzias and Jack Cush discuss autoinflammatory highlights from the Virtual EULAR 2020 meeting June 3-6
These were my top abstracts from Thursday, 4th of June at EULAR 2020:
Long Delays in Denosumab Increase Fracture Risk (SAT0453). A UK population based study looked at risk of fracture in adults…
These were my top abstracts from Thursday, 4th of June at EULAR 2020:
Voclosporin Effective in Lupus Nephritis (OP0277). Voclosporin is a calcineurin inhibitor that has performed well in an earlier…
Every time a big scientific meeting ends I ask myself a question: how is it going to affect the way I treat my patients? This year the question pertains to management of axial spondyloarthropathies…
Here is my top-five from day one at EULAR:
Merkel PA, et al. (OP0011) Avacopan as effective as steroids in ANCA Associated Vasculitis (AAV) – 330 patient RCT where AAV was treated with either with…
Updated EULAR Recommendations for RA Management
Dr. Kathryn Dao from EULAR2020 Virtual Conference
Therapeutic Update
Presented here is an update on the longer-term safety profile of upadacitinib, drawing on the integrated analysis of up to ~3.5 years of exposure data from five Phase 3 studies. Dr. Winthrop and Dr. Cush provide additional information from relevant EULAR 2020 posters.
Read Post
Featured Video
Images from EULAR2020
